992P Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)

Zhanhui Qing, Hye Ryun Kim, Ross A. Soo, C.H. Chiu, Hideki Hayashi, S-W. Kim, Shunsuke Teraoka, Dongwook Kim, H. Zhan, Houcheng Zhao, H. Li, Tony Mok, Yi‐Long Wu